Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC)

Investigational New Drugs

Volumn 23, Issue 1, 2005, Pages 79-84

  Latif, Tahir ^a   Wood, Laura ^a   Connell, Cindy ^b   Smith, David C ^c   Vaughn, David ^d   Lebwohl, David ^e   Peereboom, David ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Hormone refractory prostate cancer (HRPC); JM 216 (BMS 18751, Satraplatin); Phase II Open label study; Prostate specific antigen (PSA)

Indexed keywords

ANTIANDROGEN; SATRAPLATIN;

ADULT; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CYTOPENIA; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MYALGIA; MYELODYSPLASTIC SYNDROME; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; THROMBOCYTOPENIA; TOXICITY; TUMOR GROWTH;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; ORGANOPLATINUM COMPOUNDS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SAFETY; TREATMENT OUTCOME;

EID: 8644219658     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:DRUG.0000047109.76766.84     Document Type: Article

References (29)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ: Cancer statistics, 2003. CA Cancer J Clin 53: 5-26, 2003
2. Cho D, Di Blasio CJ, Rhee AC, Kattan MW: Prognostic factors for survival in patients with hormone-refractory prostate cancer (HRPC) after initial androgen deprivation therapy (ADT). Urol Oncol 21: 282-291, 2003
3. Eisenberger MA, Bezerdjian L, Kalash SA: Critical assessment of the role of chemotherapy for endocrine-resistant prostatic carcinoma. Urol Clin North Am 14: 695-706, 1987
4. Tannock IF: Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate? J Clin Oncol 3: 1013-1021, 1985.
5. Yagoda A, Petrylak D: Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 71: 1098-1109, 1993
6. Tolcher AW: New therapeutic strategies for prostate cancer: Reasons for optimism and reflection. Invest New Drugs 20: 143-144, 2002
7. Amorino GP, Mohr PJ, Hercules SK, Pyo H, Choy H: Combined effects of the orally active cisplatin analog, JM216, and radiation in antitumor therapy. Cancer Chemother Pharmacol 46: 423-426, 2000
8. Rose WC, Crosswell AR, Schurig JE, Casazza AM: Preclinical antitumor activity of orally administered platinum (IV) complexes. Cancer Chemother Pharmacol 32: 197-203, 1993
9. Kelland LR, Abel G, McKeage MJ, Jones M, Goddard PM, Valenti M, Murrer BA, Harrap KR: Preclinical antitumor evaluation of bis-acetato-ammine-dichloro- cyclohexylamine platinum(IV): An orally active platinum drug. Cancer Res 53: 2581-2586, 1993
10. McKeage MJ, Raynaud F, Ward J, Berry C, O'Dell D, Kelland LR, Murrer B, Santabarabara P, Harrap KR, Judson IR: Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer. J Clin Oncol, 15: 2691-2700, 1997
11. Kurata T, Tamura T, Sasaki Y, Fujii H, Negoro S, Fukuoka M, Saijo N: Pharmacokinetic and pharmacodynamic analysis of bis-acetato-ammine-dichloro- cyclohexylamine-platinum(IV) (JM216) administered once a day for five consecutive days: A phase I study. Jpn J Clin Oncol 30: 377-384, 2000
12. Kelly WK, Curley T, Slovin S, Heller G, McCaffrey J, Bajorin D, Ciolino A, Regan K, Schwartz M, Kantoff P, George D, Oh W, Smith M, Kaufman D, Small EJ, Schwartz L, Larson S, Tong W, Scher H: Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol 19: 44-53, 2001
13. Canobbio L, Guarneri D, Miglietta L, Decensi A, Oneto F, Boccardo F: Carboplatin in advanced hormone refractory prostatic cancer patients. Eur J Cancer 29A: 2094-2096, 1993
14. Rossof AH, Talley RW, Stephens R, Thigpen T, Samson MK, Groppe CJ, Eyre HJ, Fisher R: Phase II evaluation of cis-dichlorodiammineplatinum(II) in advanced malignancies of the genitourinary and gynecologic organs: A Southwest Oncology Group Study. Cancer Treat Rep 63: 1557-1564, 1979
15. Merrin CE: Treatment of previously untreated (by hormonal manipulation) stage D adenocarcinoma of prostate with combined orchiectomy, estrogen, and cis diamminedichloroplatinum. Urology 15: 123-126, 1980
16. Moore MR, Troner MB, DeSimone P, Birch R, Irwin L: Phase II evaluation of weekly cisplatin in metastatic hormone-resistant prostate cancer: A Southeastern Cancer Study Group Trial. Cancer Treat Rep 70: 541-542, 1986
17. Yogoda A: Phase II trials with cis-dichlorodiammineplatinum(II) in the treatment of urothelial cancer. Cancer Treat Rep 63: 1565-1572, 1979
18. Qazi R, Khandekar J: Phase II study of cisplatin for metastatic prostate Cancer. AM J Oncol 6: 203-205, 1983
19. Fokkema E, Groen HJ, Bauer J, Uges DR, Weil C, Smith IE: Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell lung cancer. J Clin Oncol 17: 3822-3827, 1999
20. Judson I, Cerny T, Epelbaum R, Dunlop D, Smyth J, Schaefer B, Roelvink M, Kaplan S, Hanauske A: Phase II trial of the oral platinum complex JM216 in non-small-cell lung cancer: An EORTC early clinical studies group investigation. Ann Oncol 8: 604-606, 1997
21. Trudeau M, Stuart G, Hirte H, Drouin P, Plante M, Bessette P, Dulude H, Lebwohl D, Fisher B, Seymour L: A phase II trial of JM-216 in cervical cancer: An NCIC CTG study. Gynecol Oncol 84: 327-331, 2002
22. Jones S, Hainsworth J, Burris HA 3rd, Thompson D, Raefsky E, Johnson V, Calvert S, Bulanhagui C, Lebwohl D, Greco FA: Phase I study of JM-216 (an oral platinum analogue) in combination with paclitaxel in patients with advanced malignancies. Invest New Drugs 20: 55-61, 2002
23. George CM, Haraf DJ, Mauer AM, Krauss SA, Hoffman PC, Rudin C M, Szeto L, Vokes E: E. A phase I trial of the oral platinum analogue JM216 with concomitant radiotherapy in advanced malignancies of the chest. Invest New Drugs 19: 303-310, 2001
24. Dainiak N: Hematologic consequences of exposure to ionizing radiation. Exp Hematol 30: 513-528, 2002
25. Travis LB, Holowaty EJ, Bergfeldt K, Lynch CF, Kohler BA, Wiklund T, Curtis RE, Hall P, Andersson M, Pukkala E, Sturgeon J, Stovall M: Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med 340: 351-357, 1999
26. Philpott NJ, Elebute MO, Powles R, Treleaven JG, Gore M, Dainton MG, Min T, Swansbury GJ, Catovsky D: Platinum agents and secondary myeloid leukaemia: Two cases treated only with platinum-based drugs. Br J Haematol 93: 884-887, 1996
27. Morales A, Kraus AS, Bruce AW: Oestrogen therapy and serum cortisol in carcinoma of the prostate. Br J Urol 47: 283-286, 1975
28. Kelly WK, Scher HI, Mazumdar M, Pfister D, Curley T, Leibertz C, Cohen L, Vlamis V, Dnistrian A, Schwartz M: Suramin and hydrocortisone: Determining drug efficacy in androgen-independent prostate cancer. J Clin Oncol 13: 2214-2222, 1995
29. Chi KN, Gleave ME, Klasa R, Murray N, Bryce C, Lopes de Menezes DE, D'Aloisio S, Tolcher AW: A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Clin Cancer Res 7: 3920-3927, 2001